Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy (Q43035535)

12 November 2017

title

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy (English)

1 reference

12 November 2017

10

1 reference

12 November 2017

M Guzmán-Fulgencio

1

1 reference

12 November 2017

J Berenguer

2

1 reference

12 November 2017

M García-Álvarez

3

1 reference

12 November 2017

D Micheloud

4

1 reference

12 November 2017

J C López

5

1 reference

12 November 2017

J Cosín

6

1 reference

12 November 2017

I Fernández de Castro

7

1 reference

12 November 2017

P Catalán

8

1 reference

12 November 2017

P Miralles

9

1 reference

12 November 2017

publication date

26 March 2011

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

12 November 2017

published in

1 reference

12 November 2017

volume

30

1 reference

12 November 2017

issue

10

1 reference

12 November 2017

page(s)

1213-1221

1 reference

The many roles of FAS receptor signaling in the immune system

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

A vision of cell death: Fas ligand and immune privilege 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Metalloproteinase-mediated release of human Fas ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Purification and characterization of the Fas-ligand that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Management of chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Role of the Fas/FasL pathway in HIV or SIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

The multiple roles of Fas ligand in the pathogenesis of infectious diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Hepatitis C virus infection and the risk of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Circulating cell adhesion molecules and death in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Fas system and apoptosis in viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Is HIV infection a TNF receptor signalling-driven disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

CD4+ T-cell depletion in HIV infection: killed by friendly fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Molecular mechanisms of aortic wall remodeling in response to hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Association of inflammation with worsening HOMA-insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Insulin Resistance Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10096-011-1215-0

Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants

21 January 2018

1 reference

12 December 2020

Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST

1 reference

12 December 2020

In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas

1 reference

12 December 2020

Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy

1 reference

12 December 2020

Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data.

1 reference

12 December 2020

Soluble Fas in serum from patients with renal cell carcinoma

1 reference

12 December 2020

Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients

1 reference

12 December 2020

Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells

1 reference

12 December 2020

10.1007/S10096-011-1215-0

Identifiers

DOI

1 reference

Dimensions Publication ID

12 November 2017

1032437700

0 references

1 reference